Healthcare | July 05, 2022
Sanofi Global Health launches nonprofit Impact brand for 30 medicines in low-income countries
Medicines, including insulin, to be available in 40 lower-income countries
Medicines, including insulin, to be available in 40 lower-income countries
Business EPS of €1.94, up 20.5% on a reported basis and 16.1% at CER, also benefitting from an improved effective tax rate
Beyond the technical leadership from F1, the collaboration will bring a specific focus on the people dimension of high performance
Sanofi’s DE&I Board will include three of the most influential voices in the DE&I space as Board members appointed for 3 years: organizational psychologist & best-selling author John Amaechi, award-winning social entrepreneur Caroline Casey, and DE&I pioneer and renowned thought-leader Dr. Rohini Anand
Sanofi unveiled a new bold and unifying corporate brand that supports the modernization and transformation the company launched in December 2019
Advances deployment of mRNA technology across vaccines and therapeutics development
Subscribe To Our Newsletter & Stay Updated
